{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:57:02Z","timestamp":1792803422753,"version":"4.5.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100021051","name":"Cabaletta Bio Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100021051","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Advances"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.omta.2025.201663","type":"journal-article","created":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T16:44:43Z","timestamp":1766767483000},"page":"201663","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Case study of resecabtagene autoleucel in a subject with diffuse cutaneous systemic sclerosis treated in the RESET-SSc trial"],"prefix":"10.1016","volume":"34","author":[{"given":"Daniel","family":"Nunez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenell R.","family":"Volkov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtney","family":"Little","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monalisa","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-Suen","family":"Tsou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Furmanak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Poulami","family":"Dey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lam C.","family":"Tsoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carleigh","family":"Zahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachael","family":"Bogle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuli","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Stadanlick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mallorie","family":"Werner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary","family":"Vorndran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larissa","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Ellis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jazmean","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Cicarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Flannagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Kobulsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quynh","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Schmitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Nezhad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominick","family":"Braccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tania Gonzalez","family":"Rivera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raj","family":"Tummala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann E.","family":"Gudjonsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gwendolyn","family":"Binder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-0109-7997","authenticated-orcid":false,"given":"Samik","family":"Basu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinesh","family":"Khanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omta.2025.201663_bib1","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.berh.2018.08.005","article-title":"Update on the epidemiology, risk factors, and disease outcomes of systemic sclerosis","volume":"32","author":"Ingegnoli","year":"2018","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"key":"10.1016\/j.omta.2025.201663_bib2","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1093\/rheumatology\/keac578","article-title":"The role of B cells in the pathogenesis of systemic sclerosis: an update","volume":"62","author":"Sakkas","year":"2023","journal-title":"Rheumatology"},{"key":"10.1016\/j.omta.2025.201663_bib3","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1007\/s12016-021-08889-8","article-title":"Current Concepts on the Pathogenesis of Systemic Sclerosis","volume":"64","author":"Truchetet","year":"2023","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"10.1016\/j.omta.2025.201663_bib4","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2015.2","article-title":"Systemic sclerosis","volume":"1","author":"Allanore","year":"2015","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.omta.2025.201663_bib5","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1186\/s13075-021-02548-1","article-title":"Clinical characteristics, visceral involvement, and mortality in at-risk or early diffuse systemic sclerosis: a longitudinal analysis of an observational prospective multicenter US cohort","volume":"23","author":"Jaafar","year":"2021","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.omta.2025.201663_bib6","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/cei.13238","article-title":"The immunopathogenesis of fibrosis in systemic sclerosis","volume":"195","author":"Brown","year":"2019","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.omta.2025.201663_bib7","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.925741","article-title":"Pathogenetic Aspects of Systemic Sclerosis: A View Through the Prism of B Cells","volume":"13","author":"Melissaropoulos","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omta.2025.201663_bib8","doi-asserted-by":"crossref","first-page":"272","DOI":"10.3389\/fimmu.2015.00272","article-title":"Pathogenesis of Systemic Sclerosis","volume":"6","author":"Pattanaik","year":"2015","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omta.2025.201663_bib9","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.938785","article-title":"Involvement of B cells in the development of systemic sclerosis","volume":"13","author":"Yoshizaki","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omta.2025.201663_bib10","doi-asserted-by":"crossref","first-page":"e489","DOI":"10.1016\/S2665-9913(21)00107-7","article-title":"Safety and efficacy of rituximab in systemic sclerosis (DESIRES): a double-blind, investigator-initiated, randomised, placebo-controlled trial","volume":"3","author":"Ebata","year":"2021","journal-title":"Lancet. Rheumatol."},{"key":"10.1016\/j.omta.2025.201663_bib11","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S2213-2600(22)00359-9","article-title":"Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial","volume":"11","author":"Maher","year":"2023","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.omta.2025.201663_bib12","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1093\/rheumatology\/keaa550","article-title":"Rituximab in the treatment of systemic sclerosis-related interstitial lung disease: a systematic review and meta-analysis","volume":"60","author":"Goswami","year":"2021","journal-title":"Rheumatology"},{"key":"10.1016\/j.omta.2025.201663_bib13","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.kint.2019.12.025","article-title":"Anti-CD20-mediated B-cell depletion in autoimmune diseases: successes, failures and future perspectives","volume":"97","author":"Crickx","year":"2020","journal-title":"Kidney Int."},{"key":"10.1016\/j.omta.2025.201663_bib14","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1136\/annrheumdis-2018-214898","article-title":"Non-response to rituximab therapy in rheumatoid arthritis is associated with incomplete disruption of the B cell receptor repertoire","volume":"78","author":"Pollastro","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.omta.2025.201663_bib15","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1136\/ard-2024-226142","article-title":"CD19-CAR T-cell therapy induces deep tissue depletion of B cells","volume":"84","author":"Tur","year":"2025","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.omta.2025.201663_bib16","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1016\/S2665-9913(24)00282-0","article-title":"CD19-targeting CAR T-cell therapy in patients with diffuse systemic sclerosis: a case series","volume":"7","author":"Auth","year":"2025","journal-title":"Lancet. Rheumatol."},{"key":"10.1016\/j.omta.2025.201663_bib17","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-Cell Therapy in Autoimmune Disease - A Case Series with Follow-up","volume":"390","author":"M\u00fcller","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omta.2025.201663_bib18","doi-asserted-by":"crossref","first-page":"3821","DOI":"10.1016\/j.ymthe.2024.09.009","article-title":"Case study of CD19 CAR T therapy in a subject with immune-mediate necrotizing myopathy treated in the RESET-Myositis phase I\/II trial","volume":"32","author":"Volkov","year":"2024","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omta.2025.201663_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2024.101267","article-title":"Preclinical specificity & activity of a fully human 41BB-expressing anti-CD19 CART- therapy for treatment-resistant autoimmune disease","volume":"32","author":"Peng","year":"2024","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omta.2025.201663_bib20","doi-asserted-by":"crossref","first-page":"11","DOI":"10.5301\/jsrd.5000231","article-title":"Standardization of the modified Rodnan skin score for use in clinical trials of systemic sclerosis","volume":"2","author":"Khanna","year":"2017","journal-title":"J. Scleroderma Relat. Disord."},{"key":"10.1016\/j.omta.2025.201663_bib21","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1477-7525-1-20","article-title":"The Stanford Health Assessment Questionnaire: dimensions and practical applications","volume":"1","author":"Bruce","year":"2003","journal-title":"Health Qual. Life Outcomes"},{"key":"10.1016\/j.omta.2025.201663_bib22","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1007\/s11136-006-0018-8","article-title":"Single-factor scoring validation for the Health Assessment Questionnaire-Disability Index (HAQ-DI) in patients with systemic sclerosis and comparison with early rheumatoid arthritis patients","volume":"15","author":"Cole","year":"2006","journal-title":"Qual. Life Res."},{"key":"10.1016\/j.omta.2025.201663_bib23","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1136\/annrheumdis-2020-219100","article-title":"New composite endpoint in early diffuse cutaneous systemic sclerosis: revisiting the provisional American College of Rheumatology Composite Response Index in Systemic Sclerosis","volume":"80","author":"Khanna","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.omta.2025.201663_bib24","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1136\/ard-2023-223952","article-title":"Treatment of a patient with severe systemic sclerosis (SSc) using CD19-targeted CAR T cells","volume":"82","author":"Bergmann","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.omta.2025.201663_bib25","first-page":"5181","article-title":"6 months-follow up data of systemic sclerosis patients treated with CD 19 targeting CAR-T cells","volume":"75","author":"Bergmann","year":"2023","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.omta.2025.201663_bib26","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1136\/annrheumdis-2016-209909","article-title":"Update of EULAR recommendations for the treatment of systemic sclerosis","volume":"76","author":"Kowal-Bielecka","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.omta.2025.201663_bib27","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1093\/rheumatology\/ker269","article-title":"Trends in mortality in patients with systemic sclerosis over 40 years: a systematic review and meta-analysis of cohort studies","volume":"51","author":"Elhai","year":"2012","journal-title":"Rheumatology"},{"key":"10.1016\/j.omta.2025.201663_bib28","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa1703327","article-title":"Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma","volume":"378","author":"Sullivan","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omta.2025.201663_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2023.08.023","article-title":"Cytokine and reactivity profiles in SLE patients following anti-CD19 CART therapy","volume":"31","author":"Nunez","year":"2023","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omta.2025.201663_bib30","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.4049\/jimmunol.1901120","article-title":"BAFF Produced by Neutrophils and Dendritic Cells Is Regulated Differently and Has Distinct Roles in Antibody Responses and Protective Immunity against West Nile Virus","volume":"204","author":"Giordano","year":"2020","journal-title":"J. Immunol."},{"key":"10.1016\/j.omta.2025.201663_bib31","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1136\/annrheumdis-2021-220920","article-title":"B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial","volume":"81","author":"Furie","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.omta.2025.201663_bib32","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s41927-022-00265-z","article-title":"Coding joint: kappa-deleting recombination excision circle ratio and B cell activating factor level: predicting juvenile dermatomyositis rituximab response, a proof-of-concept study","volume":"6","author":"Ochfeld","year":"2022","journal-title":"BMC Rheumatol."},{"key":"10.1016\/j.omta.2025.201663_bib33","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1136\/ard.2006.060772","article-title":"Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF production","volume":"66","author":"Lavie","year":"2007","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.omta.2025.201663_bib34","doi-asserted-by":"crossref","DOI":"10.1186\/ar2965","article-title":"B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial","volume":"12","author":"Bosello","year":"2010","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.omta.2025.201663_bib35","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.3389\/fimmu.2019.02458","article-title":"Challenges and Opportunities for Consistent Classification of Human B Cell and Plasma Cell Populations","volume":"10","author":"Sanz","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omta.2025.201663_bib36","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.clim.2007.11.013","article-title":"Transitional B cells in humans: characterization and insight from B lymphocyte reconstitution after hematopoietic stem cell transplantation","volume":"127","author":"Marie-Cardine","year":"2008","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.omta.2025.201663_bib37","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1136\/annrheumdis-2023-eular.3842","article-title":"First evidence for efficacy of CAR T cell treatment in refractory antisynthetase syndrome [abstract]","volume":"82","author":"Taubmann","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.omta.2025.201663_bib38","first-page":"1635","article-title":"A randomised, parallel-group, double-blind, placebo-controlled phase 3 study to Determine the effectiveness of the type I interferon receptor antibody, Anifrolumab, In SYstemic sclerosis: DAISY study design and rationale","volume":"42","author":"Khanna","year":"2024","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.omta.2025.201663_bib39","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.exphem.2020.07.003","article-title":"Analysis of IL-6 serum levels and CAR T cell-specific digital PCR in the context of cytokine release syndrome","volume":"88","author":"Pabst","year":"2020","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.omta.2025.201663_bib40","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.omta.2025.201663_bib41","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1002\/acr.25056","article-title":"Patient and Physician Global Assessments of Disease Status in Systemic Sclerosis","volume":"75","author":"Ross","year":"2023","journal-title":"Arthritis Care Res."},{"key":"10.1016\/j.omta.2025.201663_bib42","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1002\/acr.20108","article-title":"Prevalence, severity, and clinical correlates of pain in patients with systemic sclerosis","volume":"62","author":"Schieir","year":"2010","journal-title":"Arthritis Care Res."},{"key":"10.1016\/j.omta.2025.201663_bib43","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0885-3924(96)00274-6","article-title":"Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system","volume":"13","author":"Yellen","year":"1997","journal-title":"J. Pain Symptom Manage."},{"key":"10.1016\/j.omta.2025.201663_bib44","first-page":"313","article-title":"[Nailfold capillaroscopy-Principles and clinical application]","volume":"81","author":"Hasseli-Frabel","year":"2022","journal-title":"Z. Rheumatol."},{"key":"10.1016\/j.omta.2025.201663_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102458","article-title":"Standardisation of nailfold capillaroscopy for the assessment of patients with Raynaud's phenomenon and systemic sclerosis","volume":"19","author":"Smith","year":"2020","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.omta.2025.201663_bib46","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3002842","article-title":"T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia","volume":"3","author":"Kalos","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omta.2025.201663_bib47","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.bdq.2014.08.001","article-title":"Determining lower limits of detection of digital PCR assays for cancer-related gene mutations","volume":"1","author":"Milbury","year":"2014","journal-title":"Biomol. Detect. Quantif."},{"key":"10.1016\/j.omta.2025.201663_bib48","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1208\/s12248-021-00560-6","article-title":"Insights on Droplet Digital PCR-Based Cellular Kinetics and Biodistribution Assay Support for CAR-T Cell Therapy","volume":"23","author":"Sugimoto","year":"2021","journal-title":"AAPS J."}],"container-title":["Molecular Therapy Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3117387X25000138?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3117387X25000138?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T20:44:45Z","timestamp":1788554685000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S3117387X25000138"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S3117387X25000138"],"URL":"https:\/\/doi.org\/10.1016\/j.omta.2025.201663","relation":{},"ISSN":["3117-387X"],"issn-type":[{"value":"3117-387X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Case study of resecabtagene autoleucel in a subject with diffuse cutaneous systemic sclerosis treated in the RESET-SSc trial","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omta.2025.201663","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"201663"}}